174 results on '"Visentini M"'
Search Results
2. PB0772 Platelet-B Cell Interactions Modulate the Antibody Response to Adenoviral and mRNA Vaccines against SARS-CoV-2
- Author
-
Pallucci, D., primary, Lombardi, L., additional, Maiorca, F., additional, Marrapodi, R., additional, Sabetta, A., additional, Scafa, N., additional, Miglionico, M., additional, Romiti, G., additional, Corica, B., additional, Piconese, S., additional, Pulcinelli, F., additional, Cangemi, R., additional, Visentini, M., additional, Basili, S., additional, and Stefanini, L., additional
- Published
- 2023
- Full Text
- View/download PDF
3. PB0802 Platelet Features that Identify Early Stages of Liver Disease Progression
- Author
-
Lombardi, L., primary, Maiorca, F., additional, Pallucci, D., additional, Marrapodi, R., additional, Sabetta, A., additional, Miglionico, M., additional, Visentini, M., additional, Romiti, G., additional, Corica, B., additional, Sperduti, N., additional, Vano, M., additional, D'amico, T., additional, Fasano, S., additional, Recchia, F., additional, Cangemi, R., additional, Pellicelli, A., additional, Basili, S., additional, and Stefanini, L., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Correction to: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia
- Author
-
Garzon, R., Pichiorri, F., Palumbo, T., Visentini, M., Aqeilan, R., Cimmino, A., Wang, H., Sun, H., Volinia, S., Alder, H., Calin, G. A., Liu, C. -G, Andreeff, M., and Croce, C. M.
- Published
- 2022
- Full Text
- View/download PDF
5. POS0541 INFLAMMATORY RHEUMATIC DISEASES (IRD) WITH ONSET AFTER SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A COHORT STUDY FROM THE COVID-19 & ASD COLLABORATIVE STUDY GROUP
- Author
-
Ursini, F., primary, Ruscitti, P., additional, Addimanda, O., additional, Foti, R., additional, Raimondo, V., additional, Murdaca, G., additional, Caira, V., additional, Pigatto, E., additional, Cuomo, G., additional, Lo Gullo, A., additional, Cavazzana, I., additional, Campochiaro, C., additional, Naclerio, C., additional, De Angelis, R., additional, Ciaffi, J., additional, Mancarella, L., additional, Brusi, V., additional, Marchetti, E., additional, Motta, F., additional, Visentini, M., additional, Lorusso, S., additional, De Santis, M., additional, De Luca, G., additional, Massaro, L., additional, Olivo, D., additional, Pellegrini, R., additional, Luppino, J. M. E., additional, DI Cola, I., additional, Varcasia, G., additional, Caso, F., additional, Reta, M., additional, Dagna, L., additional, Selmi, C., additional, Iagnocco, A., additional, Giacomelli, R., additional, Iannone, F., additional, and Ferri, C., additional
- Published
- 2023
- Full Text
- View/download PDF
6. AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS.LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT’S POPULATION
- Author
-
Gragnani, L., primary, Visentini, M., additional, Lorini, S., additional, Santini, S., additional, Lauletta, G., additional, Mazzaro, C., additional, Urraro, T., additional, Luca, Q., additional, Cacciapaglia, F., additional, Ruscitti, P., additional, Tavoni, A., additional, Marri, S., additional, Cusano, G., additional, Petraccia, L., additional, Naclerio, C., additional, Treppo, E., additional, Del Frate, G., additional, Di Cola, I., additional, Raimondo, V., additional, Scorpiniti, D., additional, Monti, M., additional, Puccetti, L., additional, Elia, G., additional, Fallahi, P., additional, Basili, S., additional, Scarpato, S., additional, Iannone, F., additional, Casato, M., additional, Antonelli, A., additional, Zignego, A. L., additional, and Ferri, C., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature
- Author
-
Mazzaro, C., Bomben, R., Visentini, M., Gragnani, L., Quartuccio, L., Saccardo, F., Sebastiani, M., Filippini, D., Lauletta, G., Monti, G., and Gattei, V.
- Subjects
HBV-related glomerulonephritis ,Cancer Research ,HBV extra-hepatic manifestations ,HBV-related cryoglobulinemia ,HBV-related vasculitis ,entecavir ,hepatitis B virus ,tenofovir ,Oncology - Abstract
ObjectiveHepatitis B virus (HBV) infection causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Furthermore, about 20% of the patients develop extrahepatic manifestations such as cryoglobulinemic vasculitis (CV), polyarteritis nodosa, non-rheumatoid arthritis, glomerulonephritis and non-Hodgkin lymphoma. This review analyzed literature data on clinical manifestations of HBV-related CV and the impact of antiviral therapy with analoques nucleotide.MethodsA PubMed search was performed to select eligible studies in the literature, up to July 2022.ResultsSome studies have analyzed clinical manifestations in HBV-related CV and have investigated the role of antiviral therapy with nucleotides analogues (NAs). Clinical manifestations of CV vary from mild to moderate (purpura, asthenia and arthralgias) to severe (leg ulcers, peripheral neuropathy, glomerulonephritis, and non-Hodking lymphoma). NAs therapy leads to suppression of HBV-DNA; therefore, it is capable of producing clinical response in the majority of patients with mild to moderate symptoms.ConclusionAntiviral therapy with NAs is the first choice for HBV suppression and control of mild to moderate disease. In severe vasculitis (glomerulonephritis, progressive peripheral neuropathy and leg ulcers), rituximab alone or with plasma-exchange is always indicated in combination with antiviral therapy.
- Published
- 2023
8. AB1169 IMMUNOMODULATORY EFFECTS OF SARS-CoV-2 VACCINATION: INCREASE OF REGULATORY T CELLS AFTER mRNA VACCINE
- Author
-
La Gualana, F., primary, Villani, F., additional, Cusano, G., additional, Gragnani, L., additional, Stefanini, L., additional, Santini, S., additional, Basili, S., additional, Casato, M., additional, Fiorilli, M., additional, and Visentini, M., additional
- Published
- 2022
- Full Text
- View/download PDF
9. POS1214 COVID-19 VACCINATION RATE AND SAFETY PROFILE IN PATIENTS AFFECTED BY MIXED CRYOGLOBULINEMIC VASCULITIS.
- Author
-
Vacchi, C., primary, Testoni, S., additional, Visentini, M., additional, Zani, R., additional, Lauletta, G., additional, Gragnani, L., additional, Filippini, D. A., additional, Mazzaro, C., additional, Fraticelli, P., additional, Quartuccio, L., additional, Padoan, R., additional, Castelnovo, L., additional, Zignego, A. L., additional, Ferri, C., additional, Hoxha, A., additional, Salvarani, C., additional, Monti, G., additional, Galli, M., additional, and Sebastiani, M., additional
- Published
- 2022
- Full Text
- View/download PDF
10. COVID-19 VACCINATION RATE AND SAFETY PROFILE IN PATIENTS AFFECTED BY MIXED CRYOGLOBULINEMIC VASCULITIS
- Author
-
Vacchi, C, Testoni, S, Visentini, M, Zani, R, Lauletta, G, Gragnani, L, Filippini, Da, Mazzaro, C, Fraticelli, P, Quartuccio, L, Padoan, R, Castelnovo, L, Zignego, Al, Ferri, C, Hoxha, A, Salvarani, C, Monti, G, Galli, M, and Sebastiani, M
- Published
- 2022
11. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis
- Author
-
Zignego, A L, Wojcik, G L, Cacoub, P, Visentini, M, Casato, M, Mangia, A, Latanich, R, Charles, E D, Gragnani, L, Terrier, B, Piazzola, V, Dustin, L B, Khakoo, S I, Busch, M P, Lauer, G M, Kim, A Y, Alric, L, Thomas, D L, and Duggal, P
- Published
- 2014
- Full Text
- View/download PDF
12. Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis
- Author
-
Scarpato, S., Sebastiani, M., Luca Quartuccio, Marson, P., Fraticelli, P., Castelnovo, L., Visentini, M., Candela, M., Mazzaro, C., Saccardo, F., Pioltelli, P., Casato, M., Filippini, D., Monti, G., and Galli, M.
- Subjects
Vasculitis ,COVID-19 Vaccines ,Autoimmunity ,COVID-19 ,Cryoglobulinaemia ,SARS-CoV-2 vaccination ,SARS-CoV-2 ,Vaccination ,Immunology ,autoimmunity ,cryoglobulinaemia, COVID-19, SARS-CoV-2 vaccination, autoimmunity ,cryoglobulinaemia ,Cryoglobulinemia ,Italy ,Rheumatology ,Humans ,Immunology and Allergy - Abstract
People with cryoglobulinaemic vasculitis (CV) have an increased risk of infections, attributed to different causes: impairment of the immune system due to the disease itself, comorbidities, and immunosuppressive therapy. Therefore, these patients may be at high risk for a more severe course of COVID-19, including hospitalisation and death. Concerns about efficacy, immunogenicity and safety of vaccines, as well as doubts, not yet fully clarified in patients with systemic autoimmune diseases, represent other important factors for a low vaccination rate in people with (CV). Indeed, providing an expert position on the issues related to SARS-CoV-2 vaccination in patients suffering from CV is of critical relevance in order to help both patients and clinicians who are treating them in making the best choice in each case. A multidisciplinary task force of the Italian Group for the Study of Cryoglobulinaemia (GISC) was convened, and through a Delphi technique produced provisional recommendations regarding SARS-CoV-2 vaccination in cryoglobulinaemic patients.
- Published
- 2021
13. Different genomic imbalances in low- and high-grade HCV-related lymphomas
- Author
-
Matteucci, C, Bracci, M, Barba, G, Carbonari, M, Casato, M, Visentini, M, Pulsoni, A, Varasano, E, Roti, G, Starza, R La, Crescenzi, B, Martelli, M F, Fiorilli, M, and Mecucci, C
- Published
- 2008
- Full Text
- View/download PDF
14. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia
- Author
-
Garzon, R, Pichiorri, F, Palumbo, T, Visentini, M, Aqeilan, R, Cimmino, A, Wang, H, Sun, H, Volinia, S, Alder, H, Calin, G A, Liu, C-G, Andreeff, M, and Croce, C M
- Published
- 2007
- Full Text
- View/download PDF
15. Cryoglobulins: putative effectors of adaptive immune response
- Author
-
Basile, U., Napodano, C., Marino, M., Gulli, F., Colantuono, S., Casato, M., Pocino, K., Basile, V., LAURA TODI, Rapaccini, G. L., and Visentini, M.
- Subjects
hepatitis C virus ,B cells ,mixed cryoglobulinaemia ,Settore MED/12 - GASTROENTEROLOGIA ,Immunology ,immunoglobulins ,biomarkers ,Hepacivirus ,Adaptive Immunity ,Hepatitis C ,cryoglobulins, mixed cryoglobulinaemia, immunoglobulins, hepatitis C virus, B cells, biomarkers ,Settore MED/05 - PATOLOGIA CLINICA ,Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA ,Rheumatology ,Cryoglobulinemia ,Immunology and Allergy ,Humans ,cryoglobulins - Abstract
Cryoglobulinaemia consists of circulating monoclonal and/or polyclonal immunoglobulins with rheumatoid factor (RF) activity that precipitate at temperatures37°C. Cryoglobulinaemic syndrome, characterised by clinical signs of systemic vasculitis, is associated with chronic infection of hepatitis C virus (HCV) and might evolve in B-cell malignancies. In about one third of all HCV infection cases, serum autoantibodies are commonly found. This is probably due directly to the transformation of infected B cells but, also, indirectly, to the viral chronic stimulation of a pool of autoreactive B cells. The pattern of IgG subclasses seems to contribute to the worsening progression of HCV infection into lymphoproliferative and/or autoimmune diseases. Many evidences showed that B cells circulating in patients with HCV-associated mixed cryoglobulinaemia (MC) are profoundly abnormal; moreover, in most of cases, normal B cells are replaced by expanded clonal B cells characterized by the low expression of CD21. After viral eradication, these cells persist in circulation and their occurrence does not correlate with serum cryoglobulins nor with vasculitis response or relapse. It is probably due to the persistence of monoclonal B cells producing RF, that in course of MC can be reactivated by circulating immune complexes, highly produced during infections or tumours. Here, we aimed to review current literature focusing the pathogenesis of MC referring to specificity and immunochemical characteristics of the immunoglobulins involved in cryoprecipitation.
- Published
- 2020
16. Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases
- Author
-
Gulli, F, primary, Napodano, C, additional, Marino, M, additional, Ciasca, G, additional, Pocino, K, additional, Basile, V, additional, Visentini, M, additional, Stefanile, A, additional, Todi, L, additional, De Spirito, M, additional, Rapaccini, G L, additional, and Basile, U, additional
- Published
- 2019
- Full Text
- View/download PDF
17. A simultaneous occurrence of Tolosa–Hunt syndrome and fibrillary glomerulonephritis: a case report
- Author
-
Gigante, A, Giannakakis, K, Visentini, M, Fiorilli, M, Barbano, B, Renzulli, R, Borghesi, F, and Cianci, R
- Published
- 2009
- Full Text
- View/download PDF
18. Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia
- Author
-
Casato, M., Carlesimo, M., Francia, A., Timarco, C., Antenucci, A., Bove, M., Martini, H., Visentini, M., Fiorilli, M., and Conti, L.
- Published
- 2008
19. Hepatitis B virus‐related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review
- Author
-
Mazzaro, C., primary, Dal Maso, L., additional, Visentini, M., additional, Gitto, S., additional, Andreone, P., additional, Toffolutti, F., additional, and Gattei, V., additional
- Published
- 2019
- Full Text
- View/download PDF
20. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy Reply
- Author
-
Zignego, A. L., Gragnani, L., Visentini, M., and Casato, M.
- Published
- 2017
21. Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases.
- Author
-
Gulli, F., Napodano, C., Marino, M., Ciasca, G., Pocino, K., Basile, V., Visentini, M., Stefanile, A., Todi, L., De Spirito, M., Rapaccini, G. L., and Basile, U.
- Subjects
RHEUMATISM ,AUTOIMMUNE diseases ,SJOGREN'S syndrome ,SYSTEMIC lupus erythematosus ,ANTIPHOSPHOLIPID syndrome ,HEPATITIS C virus ,MONOCLONAL gammopathies ,IMMUNOGLOBULIN light chains - Abstract
Summary: Several reports have highlighted the abnormal increments of serum immunoglobulin free light chains (FLCs) in the course of systemic autoimmune rheumatic diseases (SARD), but a comparative analysis among different conditions is still lacking. A strong association between elevated FLC and hepatitis C virus (HCV)‐related mixed cryoglobulinaemia (HCVMC) has been well established. Here, we aimed to analyse serum FLC levels in patients with four different SARD in comparison with HCVMC. Using a turbidimetric assay, free κ and λ chains were quantified in sera from 198 SARD patients (37 rheumatoid arthritis, RA; 47 systemic lupus erythematosus, SLE; 52 anti‐phospholipid syndrome, APS; 62 primary Sjogren's syndrome, pSS), 62 HCVMC and 50 healthy blood donors (HD). All patient groups showed increased κ levels when compared to HD: 33·5 ± 2·6 mg/l in HCVMC, 26·7 ± 2·3 mg/l in RA, 29·7 ± 1·9 mg/l in SLE, 23·8 ± 1·1 mg/l in APS, 24·2 ± 1·1 mg/l in pSS; 10·1 ± 0·6 mg/l in HD. Free λ levels displayed a significant increase only for HCVMC (20·4 ± 1·4 mg/l) and SLE (18·4 ± 1·0 mg/l) compared to HD (13·6 ± 0·9 mg/l). The increase of κ compared to λ takes into account a κ /λ ratio of 1·6 for all groups. Our results substantially analyse and strengthen the association between FLC and SARD focusing the questions regarding their role in the pathogenesis and diagnosis of human diseases. Unfortunately, the biochemical differences distinguishing normal from pathological FLC have not been identified. Production of different isotypes is probably connected to still‐unknown pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. COVID-19 AND CRYOGLOBULINEMIC VASCULITIS. LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT'S POPULATION.
- Author
-
Gragnani, L., Visentini, M., Lorini, S., Santini, S., Lauletta, G., Mazzaro, C., Urraro, T., Luca, Q., Cacciapaglia, F., Ruscitti, P., Tavoni, A., Marri, S., Cusano, G., Petraccia, L., Naclerio, C., Treppo, E., Del Frate, G., Di Cola, I., Raimondo, V., and Scorpiniti, D.
- Published
- 2023
- Full Text
- View/download PDF
23. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study
- Author
-
Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, Milito C, Trombetta AC, Visentini M, Martini H, Plebani A, Fiorilli M, IPINet Investigators, De Mattia D, Martire B, Cardinale F, Ranieri G, Silvestri F, Masi M, Cossu F, Anastasio E, Schillirò G, Matucci A, Vultaggio A, Aricò M, Pietrogrande MC, Delle Piane RM, Panisi C, Cambiaghi G, Pignata C, Putti MC, Trizzino A, Bertolini P, Consolini R, Ugazio AG, Duse M, Iacobini M, Moschese V, Cancrini C, Finocchi A, Pesce AM, Cagliuso M, Conti V, Granata G, Mitrevski M, Cecere F, Tovo PA, Martino S, Montin D, Nespoli L, Marinoni M, Pellegrini FP, Cazzola G.A., PESSION, ANDREA, Quinti., I, Soresina, A., Guerra, A., Rondelli, R., Spadaro, Giuseppe, Agostini, C., Milito, C., Trombetta, A. C., Visentini, M., Martini, H., Plebani, A., Fiorilli, M., De Mattia, D., Martire, B., Cardinale, F., Ranieri, G., Silvestri, F., Masi, M., Pession, A., Cossu, F., Anastasio, E., Schillirò, G., Matucci, A., Vultaggio, A., Aricò, M., Pietrogrande, M. C., Delle Piane, R. M., Panisi, C., Cambiaghi, G., Pignata, Claudio, Putti, M. C., Trizzino, A., Bertolini, P., Consolini, R., Ugazio, A. G., Duse, M., Iacobini, M., Moschese, V., Cancrini, C., Finocchi, A., Pesce, A. M., Cagliuso, M., Conti, V., Granata, G., Mitrevski, M., Cecere, F., Tovo, P. A., Martino, S., Montin, D., Nespoli, L., Marinoni, M., Pellegrini, F. P., Cazzola, G. A., Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, Milito C, Trombetta AC, Visentini M, Martini H, Plebani A, Fiorilli M, IPINet Investigator, De Mattia D, Martire B, Cardinale F, Ranieri G, Silvestri F, Masi M, Pession A, Cossu F, Anastasio E, Schillirò G, Matucci A, Vultaggio A, Aricò M, Pietrogrande MC, Delle Piane RM, Panisi C, Cambiaghi G, Pignata C, Putti MC, Trizzino A, Bertolini P, Consolini R, Ugazio AG, Duse M, Iacobini M, Moschese V, Cancrini C, Finocchi A, Pesce AM, Cagliuso M, Conti V, Granata G, Mitrevski M, Cecere F, Tovo PA, Martino S, Montin D, Nespoli L, Marinoni M, Pellegrini FP, and Cazzola GA.
- Subjects
Male ,bronchiectasis ,X-linked agammaglobulinemia ,Comorbidity ,Gastroenterology ,Immunoglobulin G ,0302 clinical medicine ,Agammaglobulinemia ,Risk Factors ,Immunology and Allergy ,Prospective Studies ,Child ,Prospective cohort study ,0303 health sciences ,biology ,Incidence ,common variable immunodeficiency ,Middle Aged ,3. Good health ,Treatment Outcome ,Italy ,Female ,Intravenous ,Adult ,x-linked agammaglobulinemia ,medicine.medical_specialty ,immunoglobulin replacement ,Adolescent ,effectiveness ,iga ,Immunology ,Disease-Free Survival ,Injections ,Databases ,03 medical and health sciences ,Immunoglobulin replacement, common variable immunodeficiency, X-linked agammaglobulinemia, bronchiectasis, IgA, effectiveness ,Internal medicine ,medicine ,Humans ,Risk factor ,Preschool ,Factual ,Aged ,030304 developmental biology ,Settore MED/38 - Pediatria Generale e Specialistica ,Bronchiectasis ,business.industry ,Common variable immunodeficiency ,Infant ,Pneumonia ,X-Linked ,medicine.disease ,Databases, Factual ,Injections, Intravenous ,Child, Preschool ,Immunoglobulin A ,Follow-Up Studies ,Common Variable Immunodeficiency ,Genes, X-Linked ,Genes ,biology.protein ,Trough level ,business ,030215 immunology - Abstract
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and 101 patients with X-linked agammaglobulinemia over a cumulative follow-up period of 1,365 patient-years was conducted to identify prognostic markers and risk factors for associated clinical co-morbidities, the effects of long-term immunoglobulin treatment and the IgG trough level to be maintained over time required to minimise infection risk. Overall, 21% of the patients with common variable immunodeficiencies and 24% of patients with X-linked agammaglobulinemia remained infection free during the study. A reduction of pneumonia episodes has been observed after initiation of Ig replacement. During the observation time, pneumonia incidence remained low and constant over time. Patients with pneumonia did not have significant lower IgG trough levels than patients without pneumonia, with the exception of patients whose IgG trough levels were persistently < 400 mg/dL. In X-linked agammaglobulinemia, the only co-morbidity risk factor identified for pneumonia by the final multivariable model was the presence of bronchiectasis. In common variable immunodeficiencies, our data allowed us to identify a clinical phenotype characterised by a high pneumonia risk: patients with low IgG and IgA levels at diagnosis; patients who had IgA level < 7 mg/dL and who had bronchiectasis. The effect of therapy with immunoglobulins at replacement dosage for non-infectious co-morbidities (autoimmunity, lymphocytic hyperplasia and enteropathy) remains to be established. A unique general protective trough IgG level in antibody deficiency patients will remain undefined because of the major role played by the progression of lung disease in X-linked agammaglobulinemia and in a subset of patients with common variable immunodeficiencies.
- Published
- 2011
24. QUELQUES DONNÉES SUR LE RÉGIME DU PÔ
- Author
-
Pardé, M. and Visentini, M.
- Published
- 1936
25. INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION
- Author
-
Frigeni, M., primary, Visco, C., additional, Besson, C., additional, Rattotti, S., additional, Fontaine, H., additional, Goldaniga, M., additional, Visentini, M., additional, Torres, H.A., additional, Peveling-Oberhag, J., additional, Rossotti, R., additional, Zaja, F., additional, Rigacci, L., additional, Merli, M., additional, Dorival, C., additional, Alric, L., additional, Piazza, F., additional, Gentile, M., additional, Ferrari, A., additional, Pirisi, M., additional, Tedeschi, A., additional, Defrancesco, I., additional, Ferretti, V.V., additional, Bruno, R., additional, Hermine, O., additional, and Arcaini, L., additional
- Published
- 2017
- Full Text
- View/download PDF
26. Il portico argonautico per l'incoronazione della dogaressa Morosina Grimani
- Author
-
Abbondandolo, I, Azzi Visentini, M, Barbieri, F, Basili, K, Battilotti, D, Beltramini, G, Beltramini, M, Benacchio, V, Burns, H, Cafà, V, Calabi, D, Carpeggiani, P, Cartago, G, Collavo, L, Daly Davis, M, Davis, C, Fara, G, Gleria, G, Giordano, L, Guillaume, J, Hopkins, A, Mazzoni, S, Nante, A, Oechslin, W, Pesavento, A, Puppi, L, Romanelli, G, Tiso, A, Gasparotto, D, Lippmann, W, Martinis, R, Mascolo, A, Mazzi, G, Meggiolaro, R, Molteni, E, Moretti, S, Ottenheym, K, Pagliara, PN, Rigon, F, Svalduz, E, Turolla,S, Vendramin, S., Pellegriti, Roberta, Barbieri F, Beltramini G, Abbondandolo, I, Azzi Visentini, M, Barbieri, F, Basili, K, Battilotti, D, Beltramini, G, Beltramini, M, Benacchio, V, Burns, H, Cafà, V, Calabi, D, Carpeggiani, P, Cartago, G, Collavo, L, Daly Davis, M, Davis, C, Fara, G, Gleria, G, Giordano, L, Guillaume, J, Hopkins, A, Mazzoni, S, Nante, A, Oechslin, W, Pesavento, A, Puppi, L, Romanelli, G, Tiso, A, Gasparotto, D, Lippmann, W, Martinis, R, Mascolo, A, Mazzi, G, Meggiolaro, R, Molteni, E, Moretti, S, Ottenheym, K, Pagliara, PN, Pellegriti, R, Rigon, F, Svalduz, E, Turolla,S, and Vendramin, S
- Subjects
Venezia ,Vincenzo Scamozzi ,apparati scenici ,Settore ICAR/18 - Storia Dell'Architettura - Published
- 2003
27. Il castello di San Vincentii
- Author
-
Abbondandolo, I, Azzi Visentini, M, Barbieri, F, Basili, K, Battilotti, D, Beltramini, G, Beltramini, M, Benacchio, V, Burns, H, Cafà, V, Calabi, D, Carpeggiani, P, Cartago, G, Collavo, L, Daly Davis, M, Davis, C, Fara, G, Gleria, G, Giordano, L, Guillaume, J, Hopkins, A, Mazzoni, S, Nante, A, Oechslin, W, Pesavento, A, Puppi, L, Romanelli, G, Tiso, A, Gasparotto, D, Lippmann, W, Martinis, R, Mascolo, A, Mazzi, G, Meggiolaro, R, Molteni, E, Moretti, S, Ottenheym, K, Pagliara, PN, Rigon, F, Svalduz, E, Turolla,S, Vendramin, S., Pellegriti, Roberta, Barbieri,F, Beltramini G, Abbondandolo, I, Azzi Visentini, M, Barbieri, F, Basili, K, Battilotti, D, Beltramini, G, Beltramini, M, Benacchio, V, Burns, H, Cafà, V, Calabi, D, Carpeggiani, P, Cartago, G, Collavo, L, Daly Davis, M, Davis, C, Fara, G, Gleria, G, Giordano, L, Guillaume, J, Hopkins, A, Mazzoni, S, Nante, A, Oechslin, W, Pesavento, A, Puppi, L, Romanelli, G, Tiso, A, Gasparotto, D, Lippmann, W, Martinis, R, Mascolo, A, Mazzi, G, Meggiolaro, R, Molteni, E, Moretti, S, Ottenheym, K, Pagliara, PN, Pellegriti, R, Rigon, F, Svalduz, E, Turolla,S, and Vendramin, S
- Subjects
Venezia ,Scamozzi Vincenzo ,Settore ICAR/18 - Storia Dell'Architettura ,Istria - Published
- 2003
28. Il monumento funerario del Doge Marino Grimani a San Giuseppe di Castello
- Author
-
Abbondandolo, I, Azzi Visentini, M, Barbieri, F, Basili, K, Battilotti, D, Beltramini, G, Beltramini, M, Benacchio, V, Burns, H, Cafà, V, Calabi, D, Carpeggiani, P, Cartago, G, Collavo, L, Daly Davis, M, Davis, C, Fara, G, Gleria, G, Giordano, L, Guillaume, J, Hopkins, A, Mazzoni, S, Nante, A, Oechslin, W, Pesavento, A, Puppi, L, Romanelli, G, Tiso, A, Gasparotto, D, Lippmann, W, Martinis, R, Mascolo, A, Mazzi, G, Meggiolaro, R, Molteni, E, Moretti, S, Ottenheym, K, Pagliara, PN, Rigon, F, Svalduz, E, Turolla,S, Vendramin,S, Pellegriti, Roberta, Barbieri,F, Beltramini, G, Abbondandolo, I, Azzi Visentini, M, Barbieri, F, Basili, K, Battilotti, D, Beltramini, M, Benacchio, V, Burns, H, Cafà, V, Calabi, D, Carpeggiani, P, Cartago, G, Collavo, L, Daly Davis, M, Davis, C, Fara, G, Gleria, G, Giordano, L, Guillaume, J, Hopkins, A, Mazzoni, S, Nante, A, Oechslin, W, Pesavento, A, Puppi, L, Romanelli, G, Tiso, A, Gasparotto, D, Lippmann, W, Martinis, R, Mascolo, A, Mazzi, G, Meggiolaro, R, Molteni, E, Moretti, S, Ottenheym, K, Pagliara, PN, Pellegriti, R, Rigon, F, Svalduz, E, Turolla,S, and Vendramin,S
- Subjects
Venezia ,Scamozzi Vincenzo ,Settore ICAR/18 - Storia Dell'Architettura - Published
- 2003
29. INFLAMMATORY RHEUMATIC DISEASES (IRD) WITH ONSET AFTER SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A COHORT STUDY FROM THE COVID-19 & ASD COLLABORATIVE STUDY GROUP.
- Author
-
Ursini, F., Ruscitti, P., Addimanda, O., Foti, R., Raimondo, V., Murdaca, G., Caira, V., Pigatto, E., Cuomo, G., Gullo, A. Lo, Cavazzana, I., Campochiaro, C., Naclerio, C., De Angelis, R., Ciaffi, J., Mancarella, L., Brusi, V., Marchetti, E., Motta, F., and Visentini, M.
- Published
- 2023
- Full Text
- View/download PDF
30. Robustezza delle funzioni di torsione a caldo in fibre ottiche a singolo modo
- Author
-
Galtarossa, Andrea, Palmieri, Luca, Schenato, Luca, Someda, CARLO GIACOMO, and Visentini, M.
- Published
- 2005
31. Targeting of ADAMTS5's ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis
- Author
-
Chiusaroli, R., primary, Visentini, M., additional, Galimberti, C., additional, Casseler, C., additional, Mennuni, L., additional, Covaceuszach, S., additional, Lanza, M., additional, Ugolini, G., additional, Caselli, G., additional, Rovati, L.C., additional, and Visintin, M., additional
- Published
- 2013
- Full Text
- View/download PDF
32. Different genomic imbalances in low- and high-grade HCV-related lymphomas
- Author
-
Matteucci, C, primary, Bracci, M, additional, Barba, G, additional, Carbonari, M, additional, Casato, M, additional, Visentini, M, additional, Pulsoni, A, additional, Varasano, E, additional, Roti, G, additional, Starza, R La, additional, Crescenzi, B, additional, Martelli, M F, additional, Fiorilli, M, additional, and Mecucci, C, additional
- Published
- 2007
- Full Text
- View/download PDF
33. Il giardino veneto dal tardo medioevo a oggiAnalisi storica di alcuni giardini
- Author
-
Fontana, Vincenzo and AZZI VISENTINI, M.
- Published
- 1988
34. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection
- Author
-
Arcaini L, Besson C, Marco Frigeni, Fontaine H, Goldaniga M, Casato M, Visentini M, Ha, Torres, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, and Jaccard A
35. Hepatitis B virus causes mixed cryoglobulinaemia by driving clonal expansion of innate B-cells producing a VH1-69-encoded antibody
- Author
-
Visentini, M., Pascolini, S., Mitrevski, M., Marrapodi, R., Del Padre, M., Todi, L., Camponeschi, A., Axiotis, E., Carlesimo, M., Adriano De Santis, Fiorilli, M., and Casato, M.
- Subjects
Adult ,Aged, 80 and over ,Male ,B-Lymphocytes ,Immunoglobulin Variable Region ,Middle Aged ,Hepatitis B ,Immunity, Innate ,Cryoglobulinemia ,Antibody Formation ,Humans ,Female ,Immunoglobulin Heavy Chains ,Aged - Abstract
To investigate the expression of a VH1-69-encoded idiotype, and the phenotypic and functional features of monoclonal B-cells from patients with type II mixed cryoglobulinaemia (MC) secondary to chronic hepatitis B virus (HBV) infection.B-cell immunophenotype and expression of a VH1-69-encoded idiotype were investigated by flow cytometry. B-cell proliferative responses to stimuli were investigated by the CFSE dilution assay.Two out of five patients with chronic HBV studied had massive monoclonal expansion of VH1-69-expressing B-cells. These cells had the peculiar CD21(low) phenotype and low responsiveness to stimuli typical of the VH1-69-expressing B-cells commonly expanded in MC secondary to hepatitis C virus (HCV) infection. In both patients, anti-HBV therapy led to the regression of MC and of VH1-69+ B-cell expansion.VH1-69-encoded antibodies are known to preferentially recognise a variety of viral proteins including HCV E2, influenza A virus haemagglutinin and HIV gp41/gp120, and may serve as innate first line antiviral defense. Thus, like HCV, HBV may cause MC by protracted antigenic stimulation of VH1-69-expressing B-cells.
36. Rheumatoid factor-producing CD21low anergic clonal B-cells in essential mixed cryoglobulinaemia: a model for autoantigen-driven pathogenesis of infectious and non-infectious cryoglobulinaemias
- Author
-
Del Padre, M., Minafò, Y. A., Marrapodi, R., Radicchio, G., Granata, M., alessandro camponeschi, Fiorilli, M., Quartuccio, L., Vita, S., Casato, M., Colantuono, S., and Visentini, M.
- Subjects
B-lymphocyte ,B-Lymphocytes ,Cryoglobulinemia ,Rheumatoid Factor ,cryoglobulinaemia, B-lymphocyte, B-cell receptor, rheumatoid factor, anergy ,B-cell receptor ,Humans ,Hepacivirus ,cryoglobulinaemia ,Autoantigens ,Hepatitis C ,anergy - Abstract
Essential mixed cryoglobulinaemia (EMC) is a disorder of B-cells producing rheumatoid factor (RF), and is clinically and immunologically similar to mixed cryoglobulinaemia (MC) related to hepatitis C virus (HCV-MC). We report here the first comprehensive analysis of B-cell clonality, phenotype and function in EMC.The study population included 16 patients with EMC and 24 patients with HCV-MC. Molecular analysis was done for the detection of circulating clonal B cells and for B cell receptor sequencing. B-cell phenotype, proliferative response, apoptosis and ERK signaling were analysed by flow cytometry.Molecular analysis of immunoglobulin genes rearrangements revealed circulating B-cell clones in about half of patients, on average of smaller size than those found in HCV-MC patients. Sequence analysis showed usage of the same stereotyped RF-encoding B-cell receptors frequently expressed in HCV-MC and in primary Sjögren's syndrome. B-cells with low expression of CD21 (CD21low) and unusual homing and inhibitory receptors were increased in EMC and in HCV-MC, but at a significantly lower extent in the former. The CD21low B-cells of EMC and HCV-MC patients shared functional features of exhaustion and anergy, namely reduced proliferation upon ligation of Toll-like receptor 9, high constitutive expression of phosphorylated ERK, and proneness to spontaneous apoptosis.Our findings suggest a common pathogenetic mechanism in EMC, HCV-MC and primary Sjögren's syndrome, consisting of autoantigen-driven clonal expansion and exhaustion of selected RF-producing B-cells. The more massive clonal expansion in HCV-MC may be due to co-stimulatory signals provided by the virus.
37. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases
- Author
-
Francesco Ursini, Piero Ruscitti, Vincenzo Raimondo, Rossella De Angelis, Fabio Cacciapaglia, Erika Pigatto, Domenico Olivo, Ilenia Di Cola, Felice Galluccio, Francesca Francioso, Rosario Foti, Antonio Gaetano Tavoni, Salvatore D’Angelo, Corrado Campochiaro, Francesca Motta, Maria De Santis, Silvia Bilia, Caterina Bruno, Giacomo De Luca, Marcella Visentini, Jacopo Ciaffi, Luana Mancarella, Veronica Brusi, Martina D’Onghia, Giovanna Cuomo, Enrico Fusaro, Paola Cipriani, Lorenzo Dagna, Serena Guiducci, Riccardo Meliconi, Florenzo Iannone, Annamaria Iagnocco, Roberto Giacomelli, Clodoveo Ferri, Ursini, F., Ruscitti, P., Raimondo, V., De Angelis, R., Cacciapaglia, F., Pigatto, E., Olivo, D., Di Cola, I., Galluccio, F., Francioso, F., Foti, R., Tavoni, A. G., D'Angelo, S., Campochiaro, C., Motta, F., De Santis, M., Bilia, S., Bruno, C., De Luca, G., Visentini, M., Ciaffi, J., Mancarella, L., Brusi, V., D'Onghia, M., Cuomo, G., Fusaro, E., Cipriani, P., Dagna, L., Guiducci, S., Meliconi, R., Iannone, F., Iagnocco, A., Giacomelli, R., Ferri, C., DE LUCA, Giacomo, Ursini F., Ruscitti P., Raimondo V., De Angelis R., Cacciapaglia F., Pigatto E., Olivo D., Di Cola I., Galluccio F., Francioso F., Foti R., Tavoni A.G., D'Angelo S., Campochiaro C., Motta F., De Santis M., Bilia S., Bruno C., De Luca G., Visentini M., Ciaffi J., Mancarella L., Brusi V., D'Onghia M., Cuomo G., Fusaro E., Cipriani P., Dagna L., Guiducci S., Meliconi R., Iannone F., Iagnocco A., Giacomelli R., and Ferri C.
- Subjects
Rheumatology ,COVID-19 Vaccine ,Rheumatic Diseases ,COVID-19 ,Systemic rheumatic diseases, vasculitis, vaccination, COVID-19 ,General Medicine ,Immunotherapy ,Syndrome ,Letters of Biomedical and Clinical Research ,Human - Abstract
No abstract available
- Published
- 2022
38. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups
- Author
-
Domenico Olivo, E. Pigatto, Francesca La Gualana, Giorgio Amato, Ilaria Cavazzana, Rosario Foti, Antonio Tavoni, Raffaele Brittelli, Tommaso Ferrari, Francesco Masini, Marcella Visentini, Stefano Angelo Santini, Dilia Giuggioli, Franco Franceschini, Vincenzo Raimondo, Laura Gragnani, Giuseppa Pagano Mariano, Poupak Fallahi, Vincenzo Aiello, Lorenzo Puccetti, C. Naclerio, Riccardo Meliconi, Giovanna Cuomo, Amelia Spinella, Ylenia Dal Bosco, Alessandro Antonelli, Daniela Scorpiniti, M. Vadacca, Piero Ruscitti, Milvia Casato, Elisa Visalli, Florenzo Iannone, Maurizio Caminiti, Fabio Cacciapaglia, Francesco Ursini, Clodoveo Ferri, T. Urraro, Rodolfo Caminiti, Monica Monti, Massimo L'Andolina, Giovanni Rechichi, Anna Linda Zignego, Roberto Giacomelli, Giuseppe Varcasia, Roberta Pellegrini, Franco Cozzi, Pietro Gigliotti, Giusy Elia, Ferri, C., Ursini, F., Gragnani, L., Raimondo, V., Giuggioli, D., Foti, R., Caminiti, M., Olivo, D., Cuomo, G., Visentini, M., Cacciapaglia, F., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Varcasia, G., Cavazzana, I., L'Andolina, M., Ruscitti, P., Vadacca, M., Gigliotti, P., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Dal Bosco, Y., Amato, G., Masini, F., Pagano Mariano, G., Brittelli, R., Aiello, V., Caminiti, R., Scorpiniti, D., Rechichi, G., Ferrari, T., Monti, M., Elia, G., Franceschini, F., Meliconi, R., Casato, M., Iannone, F., Giacomelli, R., Fallahi, P., Santini, S. A., Zignego, A. L., Antonelli, A., Ferri C., Ursini F., Gragnani L., Raimondo V., Giuggioli D., Foti R., Caminiti M., Olivo D., Cuomo G., Visentini M., Cacciapaglia F., Pellegrini R., Pigatto E., Urraro T., Naclerio C., Tavoni A., Puccetti L., Varcasia G., Cavazzana I., L'Andolina M., Ruscitti P., Vadacca M., Gigliotti P., La Gualana F., Cozzi F., Spinella A., Visalli E., Dal Bosco Y., Amato G., Masini F., Pagano Mariano G., Brittelli R., Aiello V., Caminiti R., Scorpiniti D., Rechichi G., Ferrari T., Monti M., Elia G., Franceschini F., Meliconi R., Casato M., Iannone F., Giacomelli R., Fallahi P., Santini S.A., Zignego A.L., and Antonelli A.
- Subjects
Male ,History ,Polymers and Plastics ,Binding Antibody Units, BAU ,Antibodies, Viral ,Gastroenterology ,Industrial and Manufacturing Engineering ,Cryoglobulinemic vasculitis, CV ,Scleroderma ,Systemic sclerosi ,Systemic lupu ,Anti-citrullinated protein antibodies, ACPA ,Systemic vasculitis ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Medicine ,Viral ,Prospective Studies ,Prospective cohort study ,Neutralizing ,education.field_of_study ,Autoimmune systemic diseases ,COVID-19 vaccine ,Cryoglobulinemic vasculitis ,Neutralizing antibodies ,Rheumatoid arthritis ,Systemic lupus ,Systemic sclerosis ,Immunogenicity ,Vaccination ,Middle Aged ,Neutralizing antibody, NAb ,Rheumatoid factor, RF ,Italy ,Female ,Rituximab ,Systemic sclerosis, SSc ,Adverse events, AEs ,2019-nCoV Vaccine mRNA-1273 ,Human ,medicine.drug ,medicine.medical_specialty ,Systemic lupus erythematosus, SLE ,Immunology ,Population ,Autoimmune systemic disease ,Autoimmune Disease ,Article ,Antibodies ,Autoimmune Diseases ,Internal medicine ,Neutralizing antibodie ,Humans ,Business and International Management ,Seroconversion ,education ,Settore BIO/10 - BIOCHIMICA ,Vaccine Potency ,Rheumatoid arthriti ,BNT162 Vaccine ,Scleroderma, Systemic ,Lupus Erythematosus ,Cryoglobulinemic vasculiti ,SARS-CoV-2 ,business.industry ,Systemic ,Systemic Vasculiti ,COVID-19 ,medicine.disease ,Antibodies, Neutralizing ,Autoimmune systemic diseases, ASD ,Prospective Studie ,World Health Organization, WHO ,Rheumatoid arthritis, RA ,Systemic Vasculitis ,business - Abstract
Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals.
- Published
- 2022
39. Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases
- Author
-
Francesca Motta, Veronica Brusi, Corrado Campochiaro, Lorenzo Dagna, Enrico Fusaro, Ilenia Di Cola, Clodoveo Ferri, Fabio Cacciapaglia, Caterina Bruno, Rosario Foti, Riccardo Meliconi, Francesca Francioso, Felice Galluccio, Serena Guiducci, Vincenzo Raimondo, Jacopo Ciaffi, Annamaria Iagnocco, Giovanna Cuomo, Giacomo De Luca, Antonio Tavoni, Francesco Ursini, Roberto Giacomelli, Maria De Santis, Silvia Bilia, Piero Ruscitti, Salvatore D'Angelo, Florenzo Iannone, Domenico Olivo, Martina D'Onghia, Rossella De Angelis, Marcella Visentini, Luana Mancarella, E. Pigatto, Ursini, F., Ruscitti, P., Raimondo, V., De Angelis, R., Cacciapaglia, F., Pigatto, E., Olivo, D., Di Cola, I., Galluccio, F., Francioso, F., Foti, R., Tavoni, A., D'Angelo, S., Campochiaro, C., Motta, F., De Santis, M., Bilia, S., Bruno, C., DE LUCA, Giacomo, Visentini, M., Ciaffi, J., Mancarella, L., Brusi, V., D'Onghia, M., Cuomo, G., Fusaro, E., Dagna, L., Guiducci, S., Meliconi, R., Iannone, F., Iagnocco, A., Giacomelli, R., Ferri, C., Ursini, Francesco, Ruscitti, Piero, Raimondo, Vincenzo, De Angelis, Rossella, Cacciapaglia, Fabio, Pigatto, Erika, Olivo, Domenico, Di Cola, Ilenia, Galluccio, Felice, Francioso, Francesca, Foti, Rosario, Tavoni, Antonio, D'Angelo, Salvatore, Campochiaro, Corrado, Motta, Francesca, De Santis, Maria, Bilia, Silvia, Bruno, Caterina, De Luca, Giacomo, Visentini, Marcella, Ciaffi, Jacopo, Mancarella, Luana, Brusi, Veronica, D'Onghia, Martina, Cuomo, Giovanna, Fusaro, Enrico, Dagna, Lorenzo, Guiducci, Serena, Meliconi, Riccardo, Iannone, Florenzo, Iagnocco, Annamaria, Giacomelli, Roberto, Ferri, Clodoveo, Ursini, F, Ruscitti, P, Raimondo, V, De Angelis, R, Cacciapaglia, F, Pigatto, E, Olivo, D, Di Cola, I, Galluccio, F, Francioso, F, Foti, R, Tavoni, A, D'Angelo, S, Campochiaro, C, Motta, F, De Santis, M, Bilia, S, Bruno, C, De Luca, G, Visentini, M, Ciaffi, J, Mancarella, L, Brusi, V, D'Onghia, M, Cuomo, G, Fusaro, E, Dagna, L, Guiducci, S, Meliconi, R, Iannone, F, Iagnocco, A, Giacomelli, R, and Ferri, C
- Subjects
Male ,medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Population ,Arthritis ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,polymyalgia rheumatica ,Immune system ,Rheumatology ,Rheumatic Diseases ,Pandemic ,medicine ,Immunology and Allergy ,Humans ,Musculoskeletal Diseases ,Covid-19 ,arthritis ,vaccination ,Intensive care medicine ,Adverse effect ,education ,education.field_of_study ,business.industry ,SARS-CoV-2 ,COVID-19 ,Female ,Middle Aged ,medicine.disease ,Vaccination ,arthriti ,Molecular mimicry ,business - Abstract
In the past months, mass vaccination represented the turning point of the global battle against the COVID-19 pandemic, an unprecedented challenge for physicians, healthcare professionals, health systems and pharmaceutical companies. More than 6 billion doses of vaccine have been administered to date, covering nearly 50% of the world’s population. Although the vaccination campaign is still thwarted by spread of fake news disseminated by a ubiquitous antivaxxer movement, accumulating real-life data1 confirm the favourable safety profile already demonstrated in phase III clinical trials.2 Despite the lack of a steady literature evidence,3 the potential role of vaccines in promoting autoimmunity continues to intrigue many researchers. The theoretical basis of this association relies on the possible molecular mimicry between macromolecular components of the vaccine and specific human proteins and the exuberant immune response elicited by adjuvants contained in vaccines.4 Adverse events (AEs) associated with COVID-19 vaccines are usually mild and mainly restricted to injection site reactions. Interestingly, among systemic AEs, arthralgia is one of the most common.2 To the best of our knowledge, only isolated cases5 of arthritis developed after COVID-19 …
- Published
- 2022
40. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
- Author
-
Luca Quartuccio, Alessandra Bortoluzzi, Carlo Alberto Scirè, Antonio Marangoni, Giulia Del Frate, Elena Treppo, Laura Castelnovo, Francesco Saccardo, Roberta Zani, Marco Candela, Paolo Fraticelli, Cesare Mazzaro, Piero Renoldi, Patrizia Scaini, Davide Antonio Filippini, Marcella Visentini, Salvatore Scarpato, Dilia Giuggioli, Maria Teresa Mascia, Marco Sebastiani, Anna Linda Zignego, Gianfranco Lauletta, Massimo Fiorilli, Milvia Casato, Clodoveo Ferri, Maurizio Pietrogrande, Pietro Enrico Pioltelli, Salvatore De Vita, Giuseppe Monti, Massimo Galli, Quartuccio, L, Bortoluzzi, A, Scire, C, Marangoni, A, Del Frate, G, Treppo, E, Castelnovo, L, Saccardo, F, Zani, R, Candela, M, Fraticelli, P, Mazzaro, C, Renoldi, P, Scaini, P, Filippini, D, Visentini, M, Scarpato, S, Giuggioli, D, Mascia, M, Sebastiani, M, Zignego, A, Lauletta, G, Fiorilli, M, Casato, M, Ferri, C, Pietrogrande, M, Pioltelli, P, De Vita, S, Monti, G, and Galli, M
- Subjects
Consensus ,Cryoglobulinemic vasculiti ,Cryoglobulin ,Cryoglobulinemic vasculitis ,Cryoglobulins ,HCV ,Mixed cryoglobulinemic syndrome ,Recommendations ,Rituximab ,Consensu ,General Medicine ,Recommendation ,Rheumatology - Abstract
Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis characterized by the proliferation of B-cell clones producing pathogenic immune complexes, called cryoglobulins. It is often secondary to hepatitis C virus (HCV), autoimmune diseases, and hematological malignancies. CV usually has a mild benign clinical course, but severe organ damage and life-threatening manifestations can occur. Recently, evidence in favor of rituximab (RTX), an anti-CD 20 monoclonal antibody, is emerging in CV: nevertheless, questions upon the safety of this therapeutic approach, especially in HCV patients, are still being issued and universally accepted recommendations that can help physicians in MCS treatment are lacking. A Consensus Committee provided a prioritized list of research questions to perform a systematic literature review (SLR). A search was made in Medline, Embase, and Cochrane library, updated to August 2021. Of 1227 article abstracts evaluated, 27 studies were included in the SLR, of which one SLR, 4 RCTs, and 22 observational studies. Seventeen recommendations for the management of mixed cryoglobulinemia with rituximab from the Italian Study Group of Cryoglobulinemia (GISC) were developed to give a valuable tool to the physician approaching RTX treatment in CV.
- Published
- 2022
41. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
- Author
-
Clodoveo Ferri, Laura Gragnani, Vincenzo Raimondo, Marcella Visentini, Dilia Giuggioli, Serena Lorini, Rosario Foti, Fabio Cacciapaglia, Maurizio Caminiti, Domenico Olivo, Giovanna Cuomo, Roberta Pellegrini, Erika Pigatto, Teresa Urraro, Caterina Naclerio, Antonio Tavoni, Lorenzo Puccetti, Ilaria Cavazzana, Piero Ruscitti, Marta Vadacca, Francesca La Gualana, Franco Cozzi, Amelia Spinella, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Francesco Masini, Giuseppa Pagano Mariano, Raffaele Brittelli, Vincenzo Aiello, Daniela Scorpiniti, Giovanni Rechichi, Giuseppe Varcasia, Monica Monti, Giusy Elia, Franco Franceschini, Milvia Casato, Francesco Ursini, Roberto Giacomelli, Poupak Fallahi, Stefano Angelo Santini, Florenzo Iannone, Carlo Salvarani, Anna Linda Zignego, Alessandro Antonelli, Ferri, C., Gragnani, L., Raimondo, V., Visentini, M., Giuggioli, D., Lorini, S., Foti, R., Cacciapaglia, F., Caminiti, M., Olivo, D., Cuomo, G., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Cavazzana, I., Ruscitti, P., Vadacca, M., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Bosco, Y. D., Amato, G., Masini, F., Mariano, G. P., Brittelli, R., Aiello, V., Scorpiniti, D., Rechichi, G., Varcasia, G., Monti, M., Elia, G., Franceschini, F., Casato, M., Ursini, F., Giacomelli, R., Fallahi, P., Santini, S. A., Iannone, F., Salvarani, C., Zignego, A. L., and Antonelli, A.
- Subjects
Autoimmune systemic diseases ,Booster vaccine ,COVID-19 vaccine ,Cryoglobulinemic vasculitis ,Neutralizing antibodies ,Rheumatoid arthritis ,Systemic lupus ,Systemic sclerosis ,Systemic vasculitis ,Antibodies, Viral ,BNT162 Vaccine ,Humans ,Immunization, Secondary ,Vaccination ,COVID-19 ,COVID-19 Vaccines ,Secondary ,Immunology ,Autoimmune systemic disease ,Antibodies ,Systemic sclerosi ,Systemic lupu ,Neutralizing antibodie ,Immunology and Allergy ,Viral ,Settore BIO/10 - BIOCHIMICA ,Rheumatoid arthriti ,Cryoglobulinemic vasculiti ,Systemic vasculiti ,Immunization ,Human - Abstract
Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients originally evaluated at the end of the first vaccination cycle (time 1), 344 individuals were re-evaluated after a 6-month period (time 2), and 244 after the booster vaccine dose (time 3). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was assessed by measuring serum IgG-neutralizing antibody (NAb) on samples obtained at the three time points in both patients and 502 age-matched controls. In the 244 ASD group that received booster vaccine and monitored over the entire follow-up, the mean serum NAb levels (time 1, 2, and 3: 696.8±52.68, 370.8±41.92, and 1527±74.16SD BAU/mL, respectively; p 
- Published
- 2022
42. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature
- Author
-
Clara Pouchelon, Marcella Visentini, Giacomo Emmi, Véronique le Guern, Luca Quartuccio, Maxime Samson, Nils Venhoff, Antoine Briantais, Milvia Casato, Emmanuel Chatelus, Marie Chilles, Maria C. Cid, Elisabeth Diot, Mikael Ebbo, Stanislas Faguer, Bernhard Hellmich, Marie Jachiet, Thomas Moulinet, François Perrin, Thomas Quémeneur, Renato Alberto Sinico, Benjamin Terrier, Pouchelon, C, Visentini, M, Emmi, G, le Guern, V, Quartuccio, L, Samson, M, Venhoff, N, Briantais, A, Casato, M, Chatelus, E, Chilles, M, Cid, M, Diot, E, Ebbo, M, Faguer, S, Hellmich, B, Jachiet, M, Moulinet, T, Perrin, F, Quemeneur, T, Sinico, R, and Terrier, B
- Subjects
Vasculitis ,Alkylating agent ,Refractory ,Cryoglobulinemia vasculiti ,Immunology ,Cryoglobulinemia vasculitis ,Alkylating agents ,Belimumab ,Rituximab ,Treatment Outcome ,Cryoglobulinemia ,Humans ,Multicenter Studies as Topic ,Immunology and Allergy ,Retrospective Studies - Abstract
Background: Glucocorticoids (GCs) plus rituximab (RTX) represent the first-line treatment of nonviral mixed cryoglobulinemia vasculitis (CryoVas). However, data on therapeutic management and outcome of patients refractory to RTX are lacking. Methods: We conducted a European collaborative retrospective multicenter study of patients with nonviral mixed CryoVas refractory to RTX and performed a literature review. Results: Twenty-six original cases and 7 additional patients from the literature were included. All patients but one had type 2 cryoglobulinemia, and causes were autoimmune disease (51%), malignant hemopathy (12%) or essential CryoVas (42%). CryoVas was primary refractory to RTX in 42%, while 58% had an initial response to RTX before immune escape. After RTX failure, patients received a median of 1 (IQR, 1–3) line of treatment, representing 65 treatment periods during follow-up. Main treatments used were GCs in 92%, alkylating agents in 43%, RTX in combination with other treatments in 46%, and belimumab in 17%. Combination of anti-CD20 plus belimumab, alkylating agents alone and anti-CD20 plus alkylating agents provided the highest rates of clinical response in 100% 82% and 73%, respectively, but showed poor immunological response, in 50%, 30% and 38%, respectively. Rates of severe infection were 57%, 9% and 0% in patients receiving anti-CD20 plus belimumab, alkylating agents alone and anti-CD20 plus alkylating agents, respectively. Conclusion: In patients with nonviral mixed CryoVas refractory to RTX, anti-CD20 plus belimumab, and alkylating agents associated or not with anti-CD20, provide the highest rates of clinical response. However, anti-CD20 plus belimumab was frequently associated with severe infections.
- Published
- 2022
43. Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review
- Author
-
Stefano Gitto, L. Dal Maso, Valter Gattei, Marcella Visentini, Cesare Mazzaro, Federica Toffolutti, Pietro Andreone, Mazzaro C., Dal Maso L., Visentini M., Gitto S., Andreone P., Toffolutti F., and Gattei V.
- Subjects
Adult ,Male ,Vasculitis ,Hepatitis B virus ,hepatitis B viru ,medicine.disease_cause ,Antiviral Agents ,cryoglobulinemia ,vasculitis ,Internal Medicine ,medicine ,Humans ,Fulminant hepatitis ,Cryoglobulinemic vasculitis ,Aged ,Aged, 80 and over ,Polyarteritis nodosa ,business.industry ,Nucleosides ,Entecavir ,Middle Aged ,Viral Load ,medicine.disease ,Hepatitis B ,Cryoglobulinemia ,digestive system diseases ,entecavir ,hepatitis B virus ,Immunology ,Female ,business ,Viral load ,medicine.drug - Abstract
Cryoglobulinemic vasculitis (CV) can develop in 1.2-4% of hepatitis B virus (HBV)-infected patients. HBV infection affects about 350 million people worldwide. It can progress from acute or fulminant hepatitis to chronic hepatitis, cirrhosis or hepatocellular carcinoma. Twenty per cent of HBV patients may develop extra-hepatic manifestations, such as polyarteritis nodosa, glomerulonephritis, dermatitis, polyarthralgias and arthritis, lung disease, aplastic anaemia. Our review focuses on the role of antiviral agent nucleot(s)ide analogues (NAs) in treatment of HBV-related CV. The studies in literature have demonstrated that NAs therapy in HBV-related CV yields high virological and satisfying clinical responses in most patients with mild-and-moderate CV, but a low response in severe CV. Overall, NAs represent a promising therapeutic option for HBV-related CV. Obtaining early suppression of HBV viral load should be the main virological and clinical goal in order to prevent organ complications and lymphoproliferative disorders.
- Published
- 2019
44. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
- Author
-
Sara Rattotti, Roberto Rossotti, Marcella Visentini, Michele Merli, Maria Goldaniga, Angela Ferrari, Luca Nassi, Francesco Piazza, Raffaele Bruno, Harrys A. Torres, Luigi Rigacci, Luca Arcaini, Mario Pirisi, Annamaria Frustaci, Virginia Valeria Ferretti, Francesco Zaja, Hélène Fontaine, Céline Dorival, Irene Defrancesco, Olivier Hermine, Carlo Visco, Caroline Besson, Marco Frigeni, Massimo Gentile, Camille Alric, Emanuele Cencini, Alessandro Pulsoni, Jan Peveling-Oberhag, Michele Milella, Frigeni, M., Besson, C., Visco, C., Fontaine, H., Goldaniga, M., Visentini, M., Pulsoni, A., Torres, H. A., Peveling-Oberhag, J., Rossotti, R., Zaja, F., Rigacci, L., Merli, M., Dorival, C., Alric, C., Piazza, F., Gentile, M., Ferrari, A., Pirisi, M., Nassi, L., Rattotti, S., Frustaci, A., Milella, M., Cencini, E., Defrancesco, I., Ferretti, V. V., Bruno, R., Hermine, O., and Arcaini, L.
- Subjects
Cancer Research ,Hepatitis C virus ,Hepacivirus ,Alpha interferon ,Lymphoproliferative disorders ,medicine.disease_cause ,NHL ,Interferon ,Medicine ,hepatitis C virus infection ,B-cell lymphoproliferative disorders ,B cell ,treatment ,biology ,business.industry ,Hematology ,Hepatitis C ,medicine.disease ,biology.organism_classification ,treatment, HCV infection ,Virology ,IFN-free ,HCV infection ,medicine.anatomical_structure ,Oncology ,business ,Diffuse large B-cell lymphoma ,medicine.drug - Abstract
not available
- Published
- 2019
45. Prospective Study on CVID Patients with Adverse Reactions to Intravenous or Subcutaneous IgG Administration
- Author
-
Federica Borghese, Helene Martini, Massimo Fiorilli, Annarosa Soresina, Vultaggio Alessandra, Isabella Quinti, Andrea Matucci, Carlo Agostini, Andrea Guerra, Alessandro Plebani, Ifigenia Sfika, Giuseppe Spadaro, Marcella Visentini, Quinti, I., Soresina, A., Agostini, C., Spadaro, Giuseppe, Matucci, A., Sfika, I., Martini, H., Borghese, F., Guerra, A., Alessandra, V., Visentini, M., Plebani, A., and Fiorilli, M.
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Intravenous treatment ,Injections, Subcutaneous ,Immunology ,adverse reaction ,Pilot Projects ,Subcutaneous immunoglobulin ,immunoglobulin therapy ,adverse reactions ,common variable immunodeficiency ,intravenous immunoglobulins ,subcutaneous immunoglobulins ,Medical microbiology ,medicine ,Humans ,Immunology and Allergy ,In patient ,Prospective Studies ,Infusions, Intravenous ,Prospective cohort study ,Aged ,biology ,business.industry ,Common variable immunodeficiency ,Immunoglobulins, Intravenous ,Middle Aged ,medicine.disease ,Surgery ,Common Variable Immunodeficiency ,Immunoglobulin G ,Anesthesia ,Cohort ,biology.protein ,Antibody ,business - Abstract
INTRODUCTION: The multicenter prospective study provides information on adverse reactions to intravenous and subcutaneous immunoglobulin treatment in a cohort of 262 patients with common variable immunodeficiency. Severe adverse reactions are a rare but unpredictable event that might occur also in patients who tolerate substitutive intravenous or subcutaneous immunoglobulin therapy for months or years. RESULTS: Subcutaneous therapy has been proved to be a safe option in the 13 patients who had to stop intravenous treatment and who remained out of immunoglobulin replacement for long periods of time. However, severe reactions to subcutaneous therapy occurred at the first or after several subcutaneous immunoglobulin administrations in 2 out of 13 patients. CONCLUSION: Therefore, patients with previous severe reactions to intravenous immunoglobulin should be considered at particularly high risk for reaction to subcutaneous administration. In these cases, switching from in-hospital administration to home self-administration should be done with extreme care.
- Published
- 2008
46. Targeting of ADAMTS5's ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis
- Author
-
C. Casseler, Marco Lanza, Sonia Covaceuszach, Lucio C. Rovati, M. Visentini, Laura Mennuni, Chiara Galimberti, R. Chiusaroli, Gianfranco Caselli, Gabriele Ugolini, Michela Visintin, Chiusaroli, R, Visentini, M, Galimberti, C, Casseler, C, Mennuni, L, Covaceuszach, S, Lanza, M, Ugolini, G, Caselli, G, Rovati, L, and Visintin, M
- Subjects
Monoclonal antibody ,ADAM Protein ,Male ,Pathology ,medicine.medical_specialty ,medicine.drug_class ,Mutant ,Biomedical Engineering ,Drug Evaluation, Preclinical ,Mice, Inbred Strains ,Osteoarthritis ,Pharmacology ,Mice, Inbred Strain ,Drug Administration Schedule ,law.invention ,Injections, Intra-Articular ,Mice ,Rheumatology ,law ,medicine ,Animals ,Orthopedics and Sports Medicine ,Animal model ,STR/ort mouse ,Aggrecan ,biology ,business.industry ,Animal ,Cartilage ,Antibodies, Monoclonal ,Histology ,Recombinant Protein ,medicine.disease ,Arthritis, Experimental ,Recombinant Proteins ,ADAM Proteins ,medicine.anatomical_structure ,ADAMTS5 ,Recombinant DNA ,biology.protein ,Disease Progression ,Osteoarthriti ,ADAMTS5 Protein ,Antibody ,business - Abstract
Objective: ADAMTS5 (aggrecanase-2) has been demonstrated to be crucial in the development of osteoarthritis (OA), by use of several mouse mutants carrying either truncated, catalytically inactive enzymes or aggrecanase-resistant mutant aggrecan. We have selected recombinant monoclonal antibodies directed against ADAMTS5, by using Intracellular Antibody Capture Technology (IACT). CRB0017 revealed very high affinity for the enzyme in Biacore analyses and very good specificity in a panel of binding assays. Therefore, we tested CRB0017 in a relevant spontaneous OA model, the STR/ort mouse. Design: STR/ort male mice were recruited at 5 months of age, and treated intra-articularly in each knee with CRB0017 1.2μg, CRB0017 12μg, or vehicle. After 6 weeks, the intra-articular administration of CRB0017 was repeated with the same doses. After 3 months from recruitment, the animals were sacrificed and the femorotibial joints processed for histology and scored in a blind fashion according to both Mankin's and the OARSI methods. Results and conclusions: All histological scores were significantly decreased in the CRB0017 12μg/knee group compared to vehicle, while administration of CRB0017 1.2μg was associated with a trend to a decrease in the same parameters. Therefore, CRB0017 administered twice in 3 months could modify the course of OA in the STR/ort mouse, by delaying cartilage breakdown as assessed histologically. The procedure of blind scoring of the histological samples clearly showed that knee intra-articular administration of CRB0017, an anti-ADAMTS5 antibody, dose-dependently improved disease progression in a relevant animal model of OA. © 2013 Osteoarthritis Research Society International.
- Published
- 2013
47. A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy
- Author
-
Caterina Ceccarini, Corrado Girmenia, Stefania De Propriis, Massimo Fiorilli, Giuseppe Giannini, Maurizio Carbonari, Stefano Pileri, Marcella Visentini, Rita Zamarchi, Felice Giangaspero, Anna Guarini, Emanuela M. Ghia, Alberto Amadori, Antonio Novelli, Elena Sabattini, Visentini M, Carbonari M, Ghia E, De Propriis S, Guarini A, Girmenia C, Giannini G, Sabattini E, Ceccarini C, Zamarchi R, Giangaspero F, Novelli A, Amadori A, Pileri SA, and Fiorilli M.
- Subjects
Cancer Research ,medicine.anatomical_structure ,Oncology ,Progressive leukoencephalopathy ,business.industry ,T cell ,Monoclonal ,Immunology ,medicine ,Hematology ,Lymphocytopenia ,medicine.disease ,business - Published
- 2006
48. Surface antigen serocleared hepatitis B virus infection increases the risk of mixed cryoglobulinemia vasculitis in male patients with chronic hepatitis C.
- Author
-
Morrone A, Fiorilli V, Cinti L, Roberto P, Ferri AL, Visentini M, Pulsoni A, Spinelli FR, De Santis A, Antonelli G, Basili S, Tosti ME, Conti F, and Casato M
- Subjects
- Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Female, Aged, Hepatitis B complications, Hepatitis B immunology, Hepatitis B epidemiology, Case-Control Studies, Hepatitis B virus immunology, Adult, Sex Factors, Hepacivirus immunology, Cryoglobulinemia immunology, Cryoglobulinemia etiology, Cryoglobulinemia blood, Hepatitis B Surface Antigens blood, Hepatitis B Surface Antigens immunology, Hepatitis C, Chronic complications, Hepatitis C, Chronic immunology, Vasculitis immunology, Vasculitis epidemiology, Vasculitis etiology
- Abstract
Mixed cryoglobulinemia vasculitis (MCV) is caused in ~90% of cases by chronic hepatitis C virus (HCV
pos MCV) and more rarely by hepatitis B virus (HBV) infection, or apparently noninfectious. HCVpos MCV develops in only ~5% of patients with chronic hepatitis C (CHC), but risk factors other than female gender have not been identified so far. We conducted a retrospective case control study investigating whether past active HBV infection, defined by hepatitis B surface antigen (HBsAg) seroclearance and anti-core antibody (HBcAb) positivity, could be a risk factor for developing HCVpos MCV. The prevalence of HBsAg seroclearance was 48% within 123 HCVpos MCV patients and 29% within 257 CHC patients (p=0.0003). Multiple logistic regression including as variables gender, birth year, age at HBV testing, cirrhosis, and hepatocellular carcinoma, confirmed an association of HBsAg seroclearance with HCVpos MCV [adjusted odds ratio (OR) 2.82, 95% confidence interval (95% CI) 1.73-4.59, p<0.0001]. Stratification by gender, however, showed that HBsAg seroclearance was associated with HCVpos MCV in male [OR 4.63, 95% CI 2.27-9.48, p<0.0001] and not in female patients [OR 1.85, 95% 95% CI 0.94-3.66, p=0.076]. HBsAg seroclearance, and more likely occult HBV infection, is an independent risk factor for HCVpos MCV in male CHC patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Morrone, Fiorilli, Cinti, Roberto, Ferri, Visentini, Pulsoni, Spinelli, De Santis, Antonelli, Basili, Tosti, Conti and Casato.)- Published
- 2024
- Full Text
- View/download PDF
49. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy.
- Author
-
Visentini M, Pica A, D'Ippolito G, Sculco E, La Gualana F, Gragnani L, Miglionico M, Mazzaro C, Fiorilli M, Basili S, Martelli M, Di Rocco A, Casato M, Gentile G, and Pulsoni A
- Subjects
- Humans, Male, Female, Hepatitis B virus metabolism, Retrospective Studies, Hepatitis B Surface Antigens, Prevalence, Hepatitis B Antibodies, Hepatitis B, Chronic complications, Hepatitis B, Chronic epidemiology, Hepatitis B epidemiology, Hepatitis B complications, Lymphoma, Large B-Cell, Diffuse diagnosis
- Abstract
Studies from high endemic areas, mostly China, indicate that surface antigen positive (HBsAg
pos ) chronic hepatitis B virus (HBV) infection is associated with an increased risk of developing diffuse large B-cell lymphoma (DLBCL), whereas studies in low endemic areas have provided conflicting results. Past infection, serologically defined by negative HBsAg and positive anti-core antibody (HBsAgneg HBcAbpos ), has also been suggested to increase the risk of B-cell non-Hodgkin's lymphoma (NHL) in high endemic areas. We retrospectively reviewed unselected clinical records of 253 patients with DLBCL (54% male, aged 60.3 ± 14.6 years at diagnosis) and 694 patients with different types of indolent B-cell NHL (46% male, aged 61.7 ± 12.8 years). Patients were seen at a single center in Italy between 2001 and 2022 and HBV serological status (HBsAg, HBsAb, HBcAb, HBeAg, HBeAb, and HBV DNA) was analyzed through enzyme-linked immunosorbent assays and molecular assays; patients infected with hepatitis C virus or human immunodeficiency virus were excluded. We used an unconditional multiple logistic regression model including as matching variables gender, age at diagnosis, immigrant status, and HBV serological status. Patients with DLBCL had, compared to indolent NHL, a higher prevalence of HBsAgpos active infection (odds ratio (OR) 2.8, 95% confidence interval (95% CI) 1.2-6.3, p = 0.014). Strikingly, patients with DLBCL had also a significantly higher prevalence of past infection (OR 2.4, 95% CI 1.5-4.0, p = 0.0006). Male gender was associated with increased risk of DLBCL independently of the HBV serological status. These findings suggest that both past and active HBV infection may increase the risk of DLBCL in a low endemic area. Our study needs confirmation by studies in areas or populations with different rates of chronic or past HBV infection., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
50. Breakthrough infections after COVID-19 vaccinations do not elicit platelet hyperactivation and are associated with high platelet-lymphocyte and low platelet-neutrophil aggregates.
- Author
-
Maiorca F, Lombardi L, Marrapodi R, Pallucci D, Sabetta A, Zingaropoli MA, Perri V, Flego D, Romiti GF, Corica B, Miglionico M, Russo G, Pasculli P, Ciardi MR, Mastroianni CM, Ruberto F, Pugliese F, Pulcinelli F, Raparelli V, Cangemi R, Visentini M, Basili S, and Stefanini L
- Abstract
Background: Severe COVID-19 is associated with an excessive immunothrombotic response and thromboinflammatory complications. Vaccinations effectively reduce the risk of severe clinical outcomes in patients with COVID-19, but their impact on platelet activation and immunothrombosis during breakthrough infections is not known., Objectives: To investigate how preemptive vaccinations modify the platelet-immune crosstalk during COVID-19 infections., Methods: Cross-sectional flow cytometry study of the phenotype and interactions of platelets circulating in vaccinated ( n = 21) and unvaccinated patients with COVID-19, either admitted to the intensive care unit (ICU, n = 36) or not (non-ICU, n = 38), in comparison to matched SARS-CoV-2-negative patients ( n = 48), was performed., Results: In the circulation of unvaccinated non-ICU patients with COVID-19, we detected hyperactive and hyperresponsive platelets and platelet aggregates with adaptive and innate immune cells. In unvaccinated ICU patients with COVID-19, most of whom had severe acute respiratory distress syndrome, platelets had high P-selectin and phosphatidylserine exposure but low capacity to activate integrin αIIbβ3, dysfunctional mitochondria, and reduced surface glycoproteins. In addition, in the circulation of ICU patients, we detected microthrombi and platelet aggregates with innate, but not with adaptive, immune cells. In vaccinated patients with COVID-19, who had no acute respiratory distress syndrome, platelets had surface receptor levels comparable to those in controls and did not form microthrombi or platelet-granulocyte aggregates but aggregated avidly with adaptive immune cells., Conclusion: Our study provides evidence that vaccinated patients with COVID-19 are not associated with platelet hyperactivation and are characterized by platelet-leukocyte aggregates that foster immune protection but not excessive immunothrombosis. These findings advocate for the importance of vaccination in preventing severe COVID-19., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.